REFERENCES
- Zempsky WT, Loiselle KA, McKay K, et al. Retrospective evaluation of
pain assessment and treatment for acute vasoocclusive episodes in
children with sickle cell disease. Pediatr Blood Cancer
2008;51:265-268.
- Collins JJ, Grier HE, Kinney HC, et al. Control of severe pain in
children with terminal malignancy. J Pediatr 1995;126:653-657.
- R3 Report: Pain assessment and management standards for hospitals.
Issue 11, August 29, 2017.
www.jointcommission.org
- Finkel JC, Pestieau SR, Quezado ZM. Ketamine as an adjuvant for
treatment of cancer pain in children and adolescents. J Pain
8:515-521.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids
for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65:1-49.
- Field JJ. Five lessons learned about long-term pain management in
adults with sickle cell disease. Hematology Am Soc Hematol Educ
Program 2017;406-411.
- Zhu H, Brodsky M, Gorman AL, Inturrisi CE. Region-specific changes in
NMDA receptor mRNA induced by chronic morphine treatment are prevented
by the co-administration of the competitive NMDA receptor antagonist
LY274614. Brain Res Mol Brain Res 2003;114:154-162.
- Ketamine pharmacology: An update (pharmacodynamics and molecular
aspects, recent findings). CNS Neurosci Ther 2013;19:370-380.
- Courade M, Bertrand A, Guerrini-Rousseau L, et al. Low-dose ketamine
adjuvant treatment for refractory pain in children, adolescents and
young adults with cancer: A pilot study. BMJ Support Palliat Care
2019;1-8.
- Kajiume T, Sera Y, Nakanuno R, et al. Continuous intravenous infusion
of ketamine and lidocaine as adjuvant analgesics in a 5-year-old
patient with neuropathic cancer pain. J Palliat Med 2012;15:719-722.
- White MC, Hommers C, Parry S, Stoddart PA. Pain management in 100
episodes of severe mucositis in children. Paediatr Anaesth
2011;21:411-416.
- James PJ, Howard RF, Williams DG. The addition of ketamine to a
morphine nurse- or patient-controlled analgesia infusion (PCANCA)
increases analgesic efficacy in children with mucositis pain. Paediatr
Anaesth 2010;20:805-811.
- Conway M, White N, St. Jean C, Zempsky WT, Steven K. Use of continuous
intravenous ketamine for end-stage cancer pain in children. J Pediatr
Onc Nurs 2009;26:100-106.
- Anghelescu DL, Oakes LL. Ketamine use for reduction of opioid
tolerance in a 5-year-old girl with end-stage abdominal neuroblastoma.
J Pain Symptom Manage 2005;30:P1-P3.
- Tsui BC, Davies D, Desai S, Malherbe S. Intravenous ketamine infusion
as an adjuvant to morphine in a 2-year-old with severe cancer pain
from metastatic neuroblastoma. J Pediatr Hematol Oncol
2004;26:678-680.
- Klepstad P, Borchgrevink P, Hval B, Flaat S, Kaasa S. Long-term
treatment with ketamine in a 12-year-old girl with severe neuropathic
pain caused by a cervical spinal tumor. J Pediatr Hematol Oncol
2001;23:616-619.
- Fine PG. Low-dose ketamine in the management of opioid non-responsive
terminal cancer pain. J Pain Symptom Manage 1999;17:296-300.
- Nobrega R, Sheehy KA, Lippold C, Rice AL, Finkel JC, Quezado ZM.
Patient characteristics affect the response to ketamine and opioids
during the treatment of vaso-occlusive episode-related pain in sickle
cell disease. Pediatr Res 2018;83:445-454.
- Neri CM, Pestieau SR, Young H, Elmi A, Finkel JC, Darbari DS. Low-dose
ketamine for children and adolescents with acute sickle cell disease
related pain: a single center experience. J Anesth Clin Res
2014;5:394-398.
- Tawfic AQ, Faris AS, Kausalya R. The role of a low-dose
ketamine-midazolam regimen in the management of severe painful crisis
in patients with sickle cell disease. J Pain Symptom Manage
2014;47:334-340.
- Zempsky W, Loiselle KA, Corsi JM, Hagstrom NJ. Use of low-dose
ketamine infusion for pediatric patients with sickle cell
disease-related pain: a case series. Clin J Pain 2010;26:163-167.
- Masaracchia MM, Sites BD, Lee J, Thomas JJ, Fernandez PG.
Subanesthetic ketamine infusions for the management of pediatric pain
in non-critical care settings: An observational analysis. Acta
Anaesthesiologica Scandinavica 2019;63:1225-1230.
- Sheehy KA, Muller EA, Lippold C, Nouraie M, Finkel JC, Quezado ZM.
Subanesthetic ketamine infusions for the treatment of children and
adolescents with chronic pain: A longitudinal study. BMC Pediatr
2105;15:198.
- Rowbotham MC. What is a “clinically meaningful” reduction in pain?
Pain 2001;94:131-132.
- Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in
pain intensity is meaningful to patients with acute pain? Pain
2003;105:151-157.
- Farrar JT, Young Jr. JP, LaMoreaux L, Werth JL, Poole RM. Clinical
importance of changes in chronic pain intensity measured on an
11-point numerical pain rating scale. Pain 2001;94:149-158.
- Myrvik MP, Brandow AM, Drendel AL, et al. Clinically meaningful
measurement of pain in children with sickle cell disease. Pediatr
Blood Cancer 2013;60:1689-1695.
- Brandow AM, DeBaun MR. Key components of pain management for children
and adults with sickle cell disease. Hematol Oncol Clin North Am
2018;32:535-550.
- Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind,
placebo-controlled study to assess the efficacy and toxicity of
subcutaneous ketamine in the management of cancer pain. J Clin Oncol
2012;30:3611-3617.
- Jackson K, Franco M, William L, et al. Ketamine and cancer pain: the
reports of my death have been greatly exaggerated. J Clin Oncol
2013;31:1373-1374
- Bredlau AL, Thakur R, Korones DN, Dworkin RH. Ketamine for pain in
adults and children with cancer: A systematic review and synthesis of
the literature. Pain Med 2013;14:1505-1517.
Supporting Material: Ketamine infusion management protocol